Axol to progress eye disease treatments with new acquisition
Stem cell technologies company Axol Bioscience has acquired the ophthalmology business of Newcells Biotech.
The acquisition of Newcells’ ophthalmology business includes its specialist team, facilities and intellectual property related to supply of proprietary iPSC-derived products and ophthalmology research services to biopharma, biotechnology and CRO customers across Europe and the US.
The platforms encompass advanced retinal organoids and 2D retinal pigment epithelium (RPE) models designed to support preclinical research and translational drug development.
Growing investment in research to discover new therapeutics for eye diseases such as age-related macular degeneration, glaucoma and rare disease has driven Axol’s strategic expansion into ophthalmology, with Phenocell previously acquired in October 2024.
Axol hopes its acquisition of Newcells will strengthen the company’s position as an independent provider of iPSC-derived in vitro models for ophthalmology drug discovery, gene therapy development, and retinal safety and toxicity studies.
The news follows Axol’s recent $2.8 million financing, led by US life sciences investor BroadOak Capital Partners, which is supporting expansion of its US commercial operations, product development and manufacturing scale-up.
“Following our recent financing and continued strong revenue growth, we are executing on a clear strategy to scale Axol internationally and deepen our scientific capabilities,” said Liam Taylor, CEO of Axol Bioscience.
“The addition of Newcells’ retinal organoid business is our third acquisition in five years and significantly enhances our ophthalmology offering, combining complementary expertise and intellectual property to create the most comprehensive independent portfolio of iPSC-derived retinal models globally.”
